Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLY-2608 in PIK3CA-mutant advanced solid tumors and breast cancer
NCT05216432Phase 1Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Dec 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of zovegalisib in solid tumor and breast cancer (7 arms), sponsored by Relay Therapeutics. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Recommended Phase 2 Dose at 24 months and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
zovegalisib
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT05216432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216432.